175 related articles for article (PubMed ID: 25023406)
1. ERCC polymorphisms and prognosis of patients with osteosarcoma.
Li J; Liu S; Wang W; Zhang K; Liu Z; Zhang C; Chen S; Wu S
Tumour Biol; 2014 Oct; 35(10):10129-36. PubMed ID: 25023406
[TBL] [Abstract][Full Text] [Related]
2. Letter regarding Li JS et al. entitled "ERCC polymorphisms and prognosis of patients with osteosarcoma".
Jian Y; Tian X; Li B; Zhou Z; Wu X
Tumour Biol; 2015 May; 36(5):3195-6. PubMed ID: 25824708
[TBL] [Abstract][Full Text] [Related]
3. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
Hao T; Feng W; Zhang J; Sun YJ; Wang G
Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
[TBL] [Abstract][Full Text] [Related]
4. Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.
Qian T; Zhang B; Qian C; He Y; Li Y
Medicine (Baltimore); 2017 May; 96(20):e6832. PubMed ID: 28514298
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
6. Association of ERCC gene polymorphism with osteosarcoma risk.
Wang G; Li J; Xu X; Gupta RK; Gao X
Afr Health Sci; 2020 Dec; 20(4):1840-1848. PubMed ID: 34394247
[TBL] [Abstract][Full Text] [Related]
7. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population.
Liu D; Liu X
Medicine (Baltimore); 2018 Dec; 97(49):e13358. PubMed ID: 30544402
[TBL] [Abstract][Full Text] [Related]
9. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
Yang LM; Li XH; Bao CF
Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
[TBL] [Abstract][Full Text] [Related]
10. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
11. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
12. Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis.
Xin Y; Hao S; Lu J; Wang Q; Zhang L
PLoS One; 2014; 9(4):e95966. PubMed ID: 24763305
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Analysis of Influence ERCC Polymorphisms Confer on the Development of Brain Tumors.
Geng P; Ou J; Li J; Liao Y; Wang N; Xie G; Sa R; Liu C; Xiang L; Liang H
Mol Neurobiol; 2016 May; 53(4):2705-14. PubMed ID: 26264164
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
15. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
16. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
17. ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.
Schrama D; Scherer D; Schneider M; Zapatka M; Bröcker EB; Schadendorf D; Ugurel S; Kumar R; Becker JC
J Invest Dermatol; 2011 Jun; 131(6):1280-90. PubMed ID: 21390047
[TBL] [Abstract][Full Text] [Related]
18. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
[TBL] [Abstract][Full Text] [Related]
19. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]